Research
Hormonal
Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.
Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.
StrongSupportsmedium confidence
The difference in LS mean risk change from baseline to week 52 was significant between both tirzepatide 10 mg (-3.2%, 95% confidence interval [CI]: -4.2%, -2.2%) and 15 mg (-3.4%, 95% CI: -4.4%, -2.4%) and placebo.
Why this rating
Based on the randomized controlled trial design of the SURMOUNT-CN trial.
Source
Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trial
Lin Zhao et al. · Diabetes Obesity and Metabolism · 2025
other · n=169Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →